Xeris Biopharma Holdings (0A8E.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0A8E.L in your mock portfolio yet.
The company is currently unprofitable, as indicated by its negative EPS of -0.11 and a correspondingly negative PE ratio of -81.88. This suggests that, despite the recent share price appreciation, fundamentals have not yet caught up, and the market is valuing the company on expectations rather than current earnings power.
The stock trades at $8.72, only slightly down (0.8%) over the last month, while sitting dramatically above its 200-day moving average of $2.36. This wide premium to the long-term moving average and the modest recent pullback together suggest a strong longer-term uptrend with some short-term consolidation.
Job openings are up 25.6% month over month to 49, signaling active investment in growth and operations. However, social media follower trends are largely flat to slightly negative on most platforms, suggesting limited recent momentum in retail or public engagement.
Overall, Xeris Biopharma’s stock presents a mixed picture: technically strong and well above its 200-day moving average, but underpinned by negative earnings and only modest alternative-data momentum. The setup looks more like a speculative growth story priced for future improvement rather than one supported by current profitability.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started